Analyst Issues Buy Rating on Alector Amid Promising Biomarker Research and Positive FDA Interactions
TD Cowen Remains a Buy on Alector (ALEC)
Alector Analyst Ratings
Goldman Sachs Maintains Alector(ALEC.US) With Sell Rating
Goldman Sachs Keeps Their Sell Rating on Alector (ALEC)
Alector Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Alector, Maintains $35 Price Target
Barclays Sticks to Their Buy Rating for Alector (ALEC)
HC Wainwright & Co. : The Alector (ALEC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $41.00 to $35.00.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $35
Cantor Fitzgerald: Reiterates Alector (ALEC.US) shareholding rating.
Alector Analyst Ratings
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
Optimistic Buy Rating for Alector's AL002 Based on Promising Alzheimer's Disease Trial Biomarkers and TREM2 Signaling Efficacy
Alector: Cautious Hold Rating Ahead of Key Clinical Trial Milestones and Financial Assessment
Alector (ALEC) Receives a Buy From Barclays
TD Cowen Sticks to Their Buy Rating for Alector (ALEC)
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Alector (ALEC) and Cytokinetics (CYTK)
Alector's Promising Pipeline and Market Potential Affirm Buy Rating
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Viking Therapeutics (VKTX) and Zimmer Biomet Holdings (ZBH)
No Data